Thea Floyd
Family · Portsmouth, OHNPI 1073054953
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 69.1% of it on its own, with 37 other manufacturers making up the rest. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $39.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- AbbVie$2K
- Novo Nordisk$986
- Pfizer$501
- Bayer$425
- Lilly USA, LLC$284
- plus $2K from 32 others
What the payments were for
- Consulting fees$8,19036%
- Travel & lodging$5,39524%
- Food & beverage$8,96040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,546 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 20 | $157,717 |
| OzempicSemaglutide | 21 | $28,953 |
| JardianceEmpagliflozin | 27 | $22,441 |
| VraylarCariprazine Hcl | 11 | $18,704 |
| MounjaroTirzepatide | 17 | $18,325 |
| FarxigaDapagliflozin Propanediol | 27 | $17,980 |
| Nurtec OdtRimegepant Sulfate | 11 | $16,561 |
| KerendiaFinerenone | 17 | $10,449 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,466 |
| Oxcarbazepine | 30 | $1,732 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,571 |
| Gabapentin | 104 | $852 |
| Duloxetine Hcl | 41 | $810 |
| Celecoxib | 22 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $986 | $28,95321 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $251 | $27,41542 claims |
| Boehringer IngelheimJardiance | $116 | $22,44127 claims |
| AbbVieVraylar | $2,304 | $18,70411 claims |
| Lilly USA, LLCMounjaro | $284 | $18,32517 claims |
| PfizerNurtec Odt | $501 | $16,56111 claims |
| BayerKerendia | $425 | $10,44917 claims |
| GSKTrelegy Ellipta | $15 | $8,46613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Portsmouth
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.